|
PL4066857T3
(pl)
|
2010-08-31 |
2023-03-20 |
Glaxosmithkline Biologicals Sa |
Pegylowane liposomy do dostarczania rna kodującego immunogen
|
|
SMT202300096T1
(it)
|
2010-08-31 |
2023-05-12 |
Glaxosmithkline Biologicals Sa |
Liposomi piccoli per la somministrazione di rna codificante un immunogeno
|
|
WO2012170930A1
(en)
|
2011-06-08 |
2012-12-13 |
Shire Human Genetic Therapies, Inc |
Lipid nanoparticle compositions and methods for mrna delivery
|
|
CA2838063C
(en)
|
2011-06-08 |
2023-07-11 |
Shire Human Genetic Therapies, Inc. |
Cleavable lipids
|
|
WO2015199952A1
(en)
|
2014-06-25 |
2015-12-30 |
Acuitas Therapeutics Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CA2984125A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
HUE067372T2
(hu)
*
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
IL286515B2
(en)
|
2015-10-28 |
2024-02-01 |
Acuitas Therapeutics Inc |
Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
|
|
EP3394030B2
(en)
|
2015-12-22 |
2025-02-12 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US20200163878A1
(en)
*
|
2016-10-26 |
2020-05-28 |
Curevac Ag |
Lipid nanoparticle mrna vaccines
|
|
EP3532097A1
(en)
*
|
2016-10-27 |
2019-09-04 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US11241490B2
(en)
|
2017-01-11 |
2022-02-08 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified RNA for inducing an immune response against zika virus
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
DK3596041T3
(da)
|
2017-03-15 |
2023-01-23 |
Modernatx Inc |
Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler
|
|
WO2018170336A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
MA47800A
(fr)
|
2017-03-17 |
2020-01-22 |
Univ Newcastle |
Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
JP7464954B2
(ja)
|
2017-04-27 |
2024-04-10 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
AU2018268859B2
(en)
|
2017-05-16 |
2024-07-25 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
MA49421A
(fr)
*
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
WO2018236849A1
(en)
|
2017-06-19 |
2018-12-27 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036000A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
CA3073211A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
CN112292395A
(zh)
|
2018-04-17 |
2021-01-29 |
库瑞瓦格股份公司 |
用于疫苗接种的新型rsv rna分子和组合物
|
|
AU2019271132A1
(en)
|
2018-05-15 |
2020-11-12 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger RNA
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
JP7488193B2
(ja)
*
|
2018-05-24 |
2024-05-21 |
トランスレイト バイオ， インコーポレイテッド |
チオエステルカチオン性脂質
|
|
CA3101484A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
WO2019232208A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
|
MA52766A
(fr)
|
2018-05-30 |
2021-04-14 |
Translate Bio Inc |
Lipides cationiques vitaminiques
|
|
AU2019277361B2
(en)
|
2018-05-30 |
2025-04-24 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
CN109142288B
(zh)
*
|
2018-07-13 |
2020-10-02 |
河南师范大学 |
利用荧光光谱法测定囊泡生成的方法
|
|
CN120514877A
(zh)
|
2018-07-23 |
2025-08-22 |
川斯勒佰尔公司 |
信使rna的干粉制剂
|
|
WO2020047061A1
(en)
|
2018-08-29 |
2020-03-05 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
US20230145188A1
(en)
|
2018-09-14 |
2023-05-11 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US12329857B2
(en)
|
2018-09-21 |
2025-06-17 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
EP3867225A1
(en)
|
2018-10-18 |
2021-08-25 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CA3112837A1
(en)
|
2018-10-19 |
2020-04-23 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger rna
|
|
AU2019374871B2
(en)
|
2018-11-09 |
2025-09-11 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
CA3117866A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
US20220016265A1
(en)
|
2018-11-09 |
2022-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
JP7483294B2
(ja)
|
2018-11-09 |
2024-05-15 |
トランスレイト バイオ， インコーポレイテッド |
層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質
|
|
CA3119449A1
(en)
|
2018-11-12 |
2020-05-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
EP3883917B1
(en)
|
2018-11-21 |
2024-01-24 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
WO2020128031A2
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
EP3908597A1
(en)
|
2019-01-07 |
2021-11-17 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
JP7523449B2
(ja)
*
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
ES2972014T3
(es)
|
2019-04-22 |
2024-06-10 |
Translate Bio Inc |
Lípidos catiónicos de tioéster
|
|
KR20250152113A
(ko)
*
|
2019-04-25 |
2025-10-22 |
인텔리아 테라퓨틱스, 인크. |
이온화 가능한 아민 지질 및 지질 나노입자
|
|
EP3962902A1
(en)
*
|
2019-05-03 |
2022-03-09 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
US20220226244A1
(en)
|
2019-05-31 |
2022-07-21 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
PH12021553076A1
(en)
|
2019-06-07 |
2023-08-14 |
Scribe Therapeutics Inc |
Engineered casx systems
|
|
EP3986460A2
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
US20220313813A1
(en)
|
2019-06-18 |
2022-10-06 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
WO2020255014A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Recombinant interleukin 12 construct and uses thereof
|
|
US20220296703A1
(en)
|
2019-06-18 |
2022-09-22 |
Janssen Sciences Ireland Unlimited Company |
Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
WO2020255062A1
(en)
|
2019-06-20 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
WO2020257716A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
KR20220078557A
(ko)
|
2019-07-08 |
2022-06-10 |
트랜슬레이트 바이오 인코포레이티드 |
개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
|
|
CA3147875A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
JP7764363B2
(ja)
|
2019-07-23 |
2025-11-05 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡ担持脂質ナノ粒子の安定性組成物および作製のプロセス
|
|
PT4013385T
(pt)
|
2019-08-14 |
2024-10-01 |
Acuitas Therapeutics Inc |
Nanopartículas de lípido melhoradas para a distribuição de ácidos nucleicos
|
|
CA3150452A1
(en)
|
2019-09-06 |
2021-03-11 |
Generation Bio Co. |
Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
|
|
KR20220101077A
(ko)
|
2019-09-19 |
2022-07-19 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 분지형 꼬리 지질 화합물 및 조성물
|
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
|
AU2020352552A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
US20210145860A1
(en)
|
2019-10-21 |
2021-05-20 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
AU2020385378A1
(en)
*
|
2019-11-22 |
2022-04-07 |
Generation Bio Co. |
Ionizable lipids and nanoparticle compositions thereof
|
|
EP4077270A4
(en)
*
|
2019-12-19 |
2024-03-13 |
Syensqo Sa |
Process for synthesis of twin-tail triamines
|
|
CA3165388A1
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
KR20220142432A
(ko)
|
2019-12-20 |
2022-10-21 |
트랜슬레이트 바이오 인코포레이티드 |
메신저 rna의 직장 전달
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
EP3886897A1
(en)
|
2020-02-04 |
2021-10-06 |
CureVac AG |
Coronavirus vaccine
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US11969480B2
(en)
|
2020-02-25 |
2024-04-30 |
Translate Bio, Inc. |
Processes of preparing mRNA-loaded lipid nanoparticles
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
KR20220154772A
(ko)
*
|
2020-03-13 |
2022-11-22 |
주식회사 바이오오케스트라 |
Pgc-1a 발현을 사용하는 진단 방법
|
|
CA3172591A1
(en)
|
2020-03-24 |
2021-09-30 |
Douglas Anthony KERR |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
KR20230003477A
(ko)
|
2020-03-24 |
2023-01-06 |
제너레이션 바이오 컴퍼니 |
비-바이러스성 dna 벡터 및 인자 ix 치료제 발현을 위한 이의 용도
|
|
AU2021241696A1
(en)
|
2020-03-27 |
2022-12-01 |
Generation Bio Co. |
Novel lipids and nanoparticle compositions thereof
|
|
WO2021198157A1
(en)
|
2020-03-30 |
2021-10-07 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
JP7681617B2
(ja)
|
2020-04-09 |
2025-05-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子組成物
|
|
FI20215508A1
(en)
|
2020-04-09 |
2021-10-10 |
Niemelae Erik Johan |
Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
EP4132591A4
(en)
|
2020-04-09 |
2024-04-24 |
Verve Therapeutics, Inc. |
Base editing of pcsk9 and methods of using same for treatment of disease
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
US12023376B1
(en)
|
2020-04-17 |
2024-07-02 |
Triad National Security, Llc |
Conserved region T cell vaccines for coronavirus and methods of use
|
|
WO2021226468A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
WO2021226463A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
CA3177940A1
(en)
|
2020-05-07 |
2021-11-11 |
Anusha DIAS |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
EP4149556A1
(en)
|
2020-05-14 |
2023-03-22 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
CN115916158A
(zh)
|
2020-05-15 |
2023-04-04 |
翻译生物公司 |
用于mRNA递送的脂质纳米颗粒配制品
|
|
AU2021275223A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc. |
Coronavirus antigen compositions and their uses
|
|
TW202208629A
(zh)
|
2020-05-20 |
2022-03-01 |
美商旗艦先鋒創新有限責任公司 |
免疫原性組成物及其用途
|
|
EP4158031A1
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
AU2021281453A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
WO2021239880A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
WO2021257595A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
PH12023550030A1
(en)
|
2020-07-08 |
2024-03-11 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
CN116096702A
(zh)
*
|
2020-07-16 |
2023-05-09 |
爱康泰生治疗公司 |
用于脂质纳米颗粒的阳离子脂质
|
|
US20230272432A1
(en)
|
2020-07-27 |
2023-08-31 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3170743A1
(en)
|
2020-08-31 |
2022-03-03 |
Susanne RAUCH |
Multivalent nucleic acid based coronavirus vaccines
|
|
CA3193746A1
(en)
|
2020-09-03 |
2022-03-10 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
US20230372440A1
(en)
|
2020-10-06 |
2023-11-23 |
Translate Bio, Inc. |
Improved process and formulation of lipid nanoparticles
|
|
WO2022081544A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
IL301890A
(en)
|
2020-10-14 |
2023-06-01 |
George Mason Res Foundation Inc |
Ionizable lipids and methods of manufacture and use thereof
|
|
EP4240326A1
(en)
|
2020-11-09 |
2023-09-13 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
EP4251129A1
(en)
|
2020-11-25 |
2023-10-04 |
Translate Bio, Inc. |
Stable liquid lipid nanoparticle formulations
|
|
AU2021392719B2
(en)
|
2020-12-03 |
2025-08-14 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
MX2023007630A
(es)
|
2020-12-23 |
2023-08-25 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de trem modificadas y usos de las mismas.
|
|
AU2021412833A1
(en)
|
2020-12-28 |
2023-07-06 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US20240123076A1
(en)
|
2021-02-08 |
2024-04-18 |
The Board Of Regents Of The University Of Texas System |
Unsaturated dendrimers compositions, related formulations, and methods of use thereof
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
US20220282279A1
(en)
*
|
2021-03-06 |
2022-09-08 |
Serhat Gumrukcu |
Compositions and methods for treating and preventing coronavirus infections
|
|
JP2024511463A
(ja)
|
2021-03-22 |
2024-03-13 |
リコード セラピューティクス，インク． |
細胞への標的送達のための組成物および方法
|
|
IL306007A
(en)
|
2021-03-23 |
2023-11-01 |
Recode Therapeutics Inc |
Polynucleotide preparations, related formulations and methods of using them
|
|
EP4313115A1
(en)
|
2021-03-25 |
2024-02-07 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
|
KR20230165276A
(ko)
|
2021-03-31 |
2023-12-05 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
|
|
US20250345524A1
(en)
|
2021-03-31 |
2025-11-13 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4319803B1
(en)
|
2021-04-08 |
2025-11-26 |
Vaxthera SAS |
Coronavirus vaccine comprising a mosaic protein
|
|
JP2024515668A
(ja)
|
2021-04-19 |
2024-04-10 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａの送達のための改善された組成物
|
|
KR20240012370A
(ko)
|
2021-04-20 |
2024-01-29 |
안자리움 바이오사이언시스 아게 |
아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
|
|
KR20240011714A
(ko)
|
2021-04-27 |
2024-01-26 |
제너레이션 바이오 컴퍼니 |
치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
CA3215963A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Yaoxin LIN |
Lipid compound and use thereof in delivery of nucleic acid
|
|
CN117642380A
(zh)
|
2021-06-14 |
2024-03-01 |
世代生物公司 |
阳离子脂质及其组合物
|
|
EP4362920A1
(en)
|
2021-07-01 |
2024-05-08 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
US20240336945A1
(en)
|
2021-07-26 |
2024-10-10 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
WO2023006999A2
(en)
|
2021-07-30 |
2023-02-02 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
WO2023023589A2
(en)
|
2021-08-18 |
2023-02-23 |
The Trustees Of The University Of Pennsylvania |
Mrna vaccines against tick salivary proteins, and methods of using same
|
|
CN115710192B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
JP2024538489A
(ja)
|
2021-09-03 |
2024-10-23 |
キュアバック エスイー |
核酸を送達するための新規な脂質ナノ粒子
|
|
EP4396355A1
(en)
|
2021-09-03 |
2024-07-10 |
GlaxoSmithKline Biologicals S.A. |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
CN115772089B
(zh)
*
|
2021-09-07 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
WO2023044333A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
TW202325263A
(zh)
|
2021-09-14 |
2023-07-01 |
美商雷納嘉德醫療管理公司 |
非環狀脂質及其使用方法
|
|
JP2024534428A
(ja)
|
2021-09-17 |
2024-09-20 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
環状ポリリボヌクレオチドを生成するための組成物及び方法
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
CA3235625A1
(en)
|
2021-10-18 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
CA3235867A1
(en)
|
2021-10-22 |
2023-04-27 |
Munir MOSAHEB |
Mrna vaccine composition
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
US20250043269A1
(en)
|
2021-11-03 |
2025-02-06 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad |
Precise Genome Editing Using Retrons
|
|
MX2024005521A
(es)
|
2021-11-08 |
2024-05-21 |
Orna Therapeutics Inc |
Composiciones de nanoparticulas de lipidos para la administracion de polinucleotidos circulares.
|
|
CN118591398A
(zh)
|
2021-11-10 |
2024-09-03 |
翻译生物公司 |
用于治疗原发性纤毛运动不良症的组合物和方法
|
|
MX2024005970A
(es)
|
2021-11-16 |
2024-08-09 |
Sail Biomedicines Inc |
Lípidos ionizables y nanopartículas lipídicas novedosos ymétodos para usarlos.
|
|
JP2024542260A
(ja)
|
2021-11-22 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
JP2024542547A
(ja)
|
2021-11-23 |
2024-11-15 |
セイル バイオメディシンズ インコーポレイテッド |
細菌由来脂質組成物およびその使用
|
|
JP2024541466A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
水痘帯状疱疹ウイルス免疫原組成物及びその使用
|
|
WO2023097003A2
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
|
CN118900845A
(zh)
|
2021-11-24 |
2024-11-05 |
旗舰创业创新六公司 |
冠状病毒免疫原组合物及其用途
|
|
EP4448485A2
(en)
|
2021-12-16 |
2024-10-23 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
KR20240122872A
(ko)
|
2021-12-16 |
2024-08-13 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자에 사용하기 위한 플루오르화 양이온성 지질
|
|
KR20240124983A
(ko)
*
|
2021-12-16 |
2024-08-19 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자에 사용하기 위한 플루오르화 양이온성 지질
|
|
KR20240118174A
(ko)
|
2021-12-17 |
2024-08-02 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변성 조건 하에서의 원형 rna의 풍부화를 위한 방법
|
|
KR20240134324A
(ko)
|
2021-12-20 |
2024-09-09 |
세일 바이오메디슨스, 인크. |
mRNA 치료 조성물
|
|
CN118679254A
(zh)
|
2021-12-22 |
2024-09-20 |
旗舰创业创新六公司 |
用于纯化多核糖核苷酸的组合物和方法
|
|
AU2022420620A1
(en)
|
2021-12-23 |
2024-07-04 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
EP4463475A2
(en)
|
2022-01-14 |
2024-11-20 |
Anjarium Biosciences AG |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
WO2023147090A1
(en)
|
2022-01-27 |
2023-08-03 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
WO2023154818A1
(en)
*
|
2022-02-09 |
2023-08-17 |
Modernatx, Inc. |
Mucosal administration methods and formulations
|
|
US20250250227A1
(en)
|
2022-02-28 |
2025-08-07 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Amino lipid compound, preparation method therefor, composition thereof and use thereof
|
|
JP2025509607A
(ja)
|
2022-03-14 |
2025-04-11 |
ジェネレーション バイオ カンパニー |
異種プライムブーストワクチン組成物及び使用の方法
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
CN116813493A
(zh)
*
|
2022-03-21 |
2023-09-29 |
苏州科锐迈德生物医药科技有限公司 |
一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
WO2023191628A1
(en)
|
2022-03-30 |
2023-10-05 |
Bioneedle Drug Delivery B.V. |
A process for storing biologically active constructs in a biodegradable material
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
EP4504252A2
(en)
|
2022-04-08 |
2025-02-12 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
CN116969851A
(zh)
*
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
|
JP2025516638A
(ja)
|
2022-05-13 |
2025-05-30 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
二本鎖ｄｎａ組成物及び関連する方法
|
|
US12064479B2
(en)
|
2022-05-25 |
2024-08-20 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
WO2023230295A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
Rna compositions for delivery of monkeypox antigens and related methods
|
|
KR20250028547A
(ko)
|
2022-05-25 |
2025-02-28 |
큐어백 에스이 |
대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
|
|
EP4518845A1
(en)
|
2022-05-30 |
2025-03-12 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
TW202411426A
(zh)
|
2022-06-02 |
2024-03-16 |
美商斯奎柏治療公司 |
經工程化的２類ｖ型ｃｒｉｓｐｒ系統
|
|
CA3257914A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc |
COMPOSITIONS AND METHODS FOR TARGETING PCSK9
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co |
Compositions of lipid nanoparticles and their uses
|
|
TW202423482A
(zh)
|
2022-06-08 |
2024-06-16 |
美商泰德治療公司 |
可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
|
|
EP4539876A2
(en)
|
2022-06-18 |
2025-04-23 |
GlaxoSmithKline Biologicals S.A. |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
KR20250040656A
(ko)
|
2022-07-06 |
2025-03-24 |
몰레큘라 악시옴, 엘엘씨 |
췌장암을 치료하기 위한 조성물 및 방법
|
|
US20250360199A1
(en)
|
2022-07-07 |
2025-11-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Immunogens and methods for inducing an immune response
|
|
EP4556460A1
(en)
|
2022-07-15 |
2025-05-21 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Amino lipid compound, preparation method therefor, composition thereof and application thereof
|
|
WO2024026308A2
(en)
|
2022-07-29 |
2024-02-01 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
|
|
AU2023320333A1
(en)
|
2022-08-01 |
2025-01-16 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
JP2025527583A
(ja)
|
2022-08-18 |
2025-08-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子の組成物
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
EP4577519A1
(en)
|
2022-08-23 |
2025-07-02 |
ModernaTX, Inc. |
Methods for purification of ionizable lipids
|
|
JP2025530781A
(ja)
|
2022-08-31 |
2025-09-17 |
セイル バイオメディシンズ インコーポレイテッド |
新規のイオン化可能な脂質および脂質ナノ粒子ならびにそれらの使用方法
|
|
IL319414A
(en)
|
2022-09-23 |
2025-05-01 |
BioNTech SE |
Compositions for delivering antigens at the liver level and related methods
|
|
CN120152736A
(zh)
|
2022-09-23 |
2025-06-13 |
生物技术欧洲股份公司 |
用于递送疟原虫csp抗原的组合物及相关方法
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
EP4598954A1
(en)
|
2022-10-06 |
2025-08-13 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024089229A1
(en)
|
2022-10-28 |
2024-05-02 |
CureVac SE |
Improved formulations comprising lipid-based carriers encapsulating rna
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
KR20250099195A
(ko)
|
2022-10-31 |
2025-07-01 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
CN120518505A
(zh)
*
|
2022-11-03 |
2025-08-22 |
上海环码生物医药有限公司 |
脂质化合物、脂质纳米颗粒和药物组合物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
CN120435298A
(zh)
|
2022-11-08 |
2025-08-05 |
旗舰创业创新第六有限责任公司 |
用于产生环状多核糖核苷酸的组合物和方法
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
CN120390656A
(zh)
|
2022-11-08 |
2025-07-29 |
欧纳医疗公司 |
环状rna组合物
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
EP4622630A1
(en)
|
2022-11-21 |
2025-10-01 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
|
WO2024119039A2
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticles and uses thereof
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
EP4626401A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
KR20250131271A
(ko)
|
2022-12-01 |
2025-09-02 |
제너레이션 바이오 컴퍼니 |
신규한 폴리글리세롤-접합된 지질 및 이를 포함하는 지질 나노입자 조성물
|
|
WO2024119098A1
(en)
*
|
2022-12-02 |
2024-06-06 |
Prime Medicine, Inc. |
Lipid nanoparticle (lnp) delivery systems and formulations
|
|
AU2023391361A1
(en)
|
2022-12-08 |
2025-06-05 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2024129988A1
(en)
|
2022-12-14 |
2024-06-20 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for delivery of therapeutic agents to bone
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
WO2024133515A1
(en)
|
2022-12-20 |
2024-06-27 |
Sanofi |
Rhinovirus mrna vaccine
|
|
WO2024133635A1
(en)
|
2022-12-23 |
2024-06-27 |
Biontech Delivery Technologies Gmbh |
Composition
|
|
EP4642797A1
(en)
|
2022-12-28 |
2025-11-05 |
BioNTech SE |
Rna compositions targeting hiv
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
CN118324841A
(zh)
|
2023-01-10 |
2024-07-12 |
辽宁键凯科技有限公司 |
一种类固醇-阳离子脂质化合物及其应用
|
|
CN118359516A
(zh)
*
|
2023-01-18 |
2024-07-19 |
尧唐(上海)生物科技有限公司 |
递送治疗剂的脂质化合物及其制备方法与应用
|
|
AU2024212425A1
(en)
|
2023-01-27 |
2025-08-07 |
Sail Biomedicines, Inc. |
A modified lipid composition and uses thereof
|
|
AU2024214423A1
(en)
|
2023-02-03 |
2025-09-18 |
Genzyme Corporation |
Hsc-specific antibody conjugated lipid nanoparticles and uses thereof
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
WO2024173307A2
(en)
|
2023-02-13 |
2024-08-22 |
Flagship Pioneering Innovation Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
US20240285805A1
(en)
|
2023-02-17 |
2024-08-29 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
|
IL322378A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA compositions containing modified cytosine
|
|
WO2024181917A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Agency For Science, Technology And Research |
A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof
|
|
KR20250153298A
(ko)
|
2023-03-08 |
2025-10-24 |
큐어백 에스이 |
핵산 전달을 위한 신규의 지질 나노입자 제형
|
|
WO2024192420A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
CN118666726A
(zh)
*
|
2023-03-17 |
2024-09-20 |
尧唐(上海)生物科技有限公司 |
递送治疗剂的脂质化合物及其制备方法与应用
|
|
WO2024206676A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024206555A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
AU2024252590A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024218166A1
(en)
|
2023-04-17 |
2024-10-24 |
Sanofi |
Reconstitutable dry powder formulations and methods of use thereof
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
AU2024265158A1
(en)
|
2023-05-03 |
2025-11-06 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2024260570A1
(en)
|
2023-06-23 |
2024-12-26 |
CureVac SE |
Nucleic acid encoded antibodies
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025006385A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel malaria vaccine comprising ama1 and ron2 antigens
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
TW202516001A
(zh)
|
2023-07-25 |
2025-04-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
Ｃａｓ內切酶及相關方法
|
|
TW202519509A
(zh)
|
2023-08-01 |
2025-05-16 |
德商拜恩技術股份公司 |
可離子化硫脂質及其用途
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025036992A1
(en)
|
2023-08-16 |
2025-02-20 |
CureVac SE |
Rna conjugates
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025043730A1
(en)
*
|
2023-09-01 |
2025-03-06 |
Yoltech Therapeutics Co., Ltd |
Lipid compounds for delivery of therapeutic agents and preparation method and use thereof
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025064475A2
(en)
|
2023-09-18 |
2025-03-27 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025088088A1
(en)
|
2023-10-27 |
2025-05-01 |
CureVac SE |
Rna composition for improving cell therapy
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025103803A1
(en)
|
2023-11-13 |
2025-05-22 |
CureVac SE |
Immunotherapy against neuronal and brain tumors
|
|
US20250162981A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
GB202416789D0
(en)
|
2023-11-15 |
2025-01-01 |
BioNTech SE |
SARS-COV-2 immunogenic compositions
|
|
WO2025106915A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
|
|
WO2025106930A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
|
|
US20250161227A1
(en)
|
2023-11-17 |
2025-05-22 |
Acuitas Therapeutics, Inc. |
Pegylated lipids
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
US20250188016A1
(en)
|
2023-12-12 |
2025-06-12 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025132122A1
(en)
|
2023-12-13 |
2025-06-26 |
Berlin Institute Of Health |
Methods of delivering therapeutics using lipid nanoparticles
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025147604A1
(en)
|
2024-01-05 |
2025-07-10 |
Arbor Biotechnologies, Inc. |
Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025174858A1
(en)
|
2024-02-15 |
2025-08-21 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025217264A1
(en)
|
2024-04-10 |
2025-10-16 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025231114A1
(en)
|
2024-05-01 |
2025-11-06 |
Acuitas Therapeutics, Inc. |
Method of using lipid nanoparticles for intramuscular delivery
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025240833A1
(en)
|
2024-05-17 |
2025-11-20 |
Acuitas Therapeutics, Inc. |
Galnac lipid compounds for use in lipid nanoparticles
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025242815A1
(en)
|
2024-05-23 |
2025-11-27 |
CureVac SE |
Immunotherapy of squamous cell carcinoma
|